Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Pirtobrutinib + Obinutuzumab for First-Line CLL: Phase 2 Study Results #CLL | EHA 2026
HealthTreeDescription
Dr. Inhye Ahn presents results from a phase 2 study combining pirtobrutinib (a next-generation BTK inhibitor) with obinutuzumab (anti-CD20 monoclonal antibody) as first-line treatment for chronic lymphocytic leukemia (CLL).
THE COMBINATION:
Two drugs working together—pirtobrutinib targets cancer cells and obinutuzumab activates the immune system to attack CLL.
WHAT MAKES THIS STUDY UNIQUE:
Fixed-duration treatment (not lifelong), plus important cardiac safety monitoring. Heart health is carefully tracked throughout treatment.
KEY FINDINGS:
- Response rates show the combination is effective
- Cardiac monitoring results provide important safety data
- Designed to balance efficacy with quality of life
WHY IT MATTERS:
For newly diagnosed CLL patients, this combination offers hope for better outcomes with a defined treatment timeline rather than continuous therapy.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction & Background
0:29 Study Details: Combination Therapy & Cardiac Testing
1:12 Study Results: Response Rates
1:39 Cardiac Findings
2:21 Conclusion
#CLL #Pirtobrutinib #BTKInhibitor #ClinicalTrial #FirstLine